Nanomaterials for cancer immunotherapy

Song, Wantong; Musetti, Sara; Huang, Leaf

doi:10.1016/j.biomaterials.2017.09.017

Cited by 232 publications

(154 citation statements)

References 272 publications

(251 reference statements)

Supporting

Mentioning

152

Contrasting

Unclassified

Order By: Relevance

“…[202,203] In addition, M2 macrophages also hamper the function of DCs and CD8+ T cells, and promote the expression of VEGF for tumor angiogenesis. High ratio of M2/M1 would in turn further raise the level of these immunosuppressive cytokines and at the same time downregulate the proinflammatory cytokines, such as IL-1β and tumor necrosis factor-α (TNF-α).…”

Section: Doi: 101002/advs201900101mentioning

confidence: 99%

Immunomodulatory Nanosystems

et al. 2019

Self Cite

View full text Add to dashboard Cite

Immunotherapy has emerged as an effective strategy for the prevention and treatment of a variety of diseases, including cancer, infectious diseases, inflammatory diseases, and autoimmune diseases. Immunomodulatory nanosystems can readily improve the therapeutic effects and simultaneously overcome many obstacles facing the treatment method, such as inadequate immune stimulation, off‐target side effects, and bioactivity loss of immune agents during circulation. In recent years, researchers have continuously developed nanomaterials with new structures, properties, and functions. This Review provides the most recent advances of nanotechnology for immunostimulation and immunosuppression. In cancer immunotherapy, nanosystems play an essential role in immune cell activation and tumor microenvironment modulation, as well as combination with other antitumor approaches. In infectious diseases, many encouraging outcomes from using nanomaterial vaccines against viral and bacterial infections have been reported. In addition, nanoparticles also potentiate the effects of immunosuppressive immune cells for the treatment of inflammatory and autoimmune diseases. Finally, the challenges and prospects of applying nanotechnology to modulate immunotherapy are discussed.

show abstract

Section: Doi: 101002/advs201900101mentioning

confidence: 99%

Immunomodulatory Nanosystems

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…For effective tumor immunotherapy, NP-based systems may combine different treatment modalities, such as chemotherapy, photodynamic therapy (PDT) and hyperthermia, as an effective therapeutic strategy. [61][62][63][64][65] Wang et al 54 Combined PD-L1 knockdown and PDT completely eliminated the B16-F10 tumors ( Figure 2E). Moreover, combined immunotherapy markedly suppressed the metastasis of B16-F10 in the lungs ( Figure 2F).…”

Section: Tumor Microenvironment-targeted Rna Interference Strategy mentioning

confidence: 91%

“…For effective tumor immunotherapy, NP‐based systems may combine different treatment modalities, such as chemotherapy, photodynamic therapy (PDT) and hyperthermia, as an effective therapeutic strategy . Wang et al .…”

Section: Tumor Microenvironment‐targeted Rna Interference Strategy Fomentioning

confidence: 99%

Non‐viral gene delivery for cancer immunotherapy

Wang

Saeed

Zhou

et al. 2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

Recent decades have witnessed the revolutionary development of cancer immunotherapies, which boost cancer‐specific immune responses for long‐term tumor regression. However, immunotherapy still has limitations, including off‐target side effects, long processing times and limited patient responses. These disadvantages of current immunotherapy are being addressed by improving our understanding of the immune system, as well as by establishing combinational approaches. Advanced biomaterials and gene delivery systems overcome some of these delivery issues, harnessing adverse effects and amplifying immunomodulatory effects, and are superior to standard formulations with respect to eliciting antitumor immunity. Nucleic acid‐based nanostructures have diverse functions, ranging from gene expression and gene regulation to pro‐inflammatory effects, as well as the ability to specifically bind different molecules. A brief overview is provided of the recent advances in the non‐viral gene delivery methods that are being used to activate cancer‐specific immune responses. Furthermore, the tumor microenvironment‐responsive synergistic strategies that modulate the immune response by targeting various signaling pathways are discussed. Nanoparticle‐based non‐viral gene delivery strategies have great potential to be implemented in the clinic for cancer immunotherapy.

show abstract

“…The nanocarriers are applied to deliver vaccines into the skin alone or in combination with physical approaches, typically the microneedles, to overcome the SC barrier and increase the antigen expression and presentation. The advantages of nanocarriers for genetic vaccines include the compression of DNA/mRNA, protection from DNase/RNase degradation, high loading capacity, a flexible size and easy functional modification . According to their composition, the commonly used nanocarriers are classified into two categories: lipid‐based and polymer‐based carriers.…”

Section: Advanced Technologies For Transcutaneous Gene Deliverymentioning

confidence: 99%

Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination

Sun

Zeng

Huang

2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

Therapeutic vaccination is a promising strategy for the immunotherapy of cancers. It eradicates cancer cells by evoking and strengthening the patient's own immune system. Because of the easy access and sophisticated immune networks, the skin becomes an ideal target organ for vaccination. Genetic vaccines have been widely investigated, with the advantages of the delivery of multiple antigens and a lower cost for production compared to protein/peptide vaccines. This review summarizes the advances made with respect to the transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination and also gives a brief description of the immunological milieu of the skin and the importance of dendritic cell‐targeting in vaccine delivery, as well as the technologies that aim to facilitate antigen delivery and modulate antigen‐presenting cells, thus improving cellular responses. The applications of genetic vaccines encoding tumor antigens delivered through the skin route, both in preclinical and clinical trials, are outlined.

show abstract

Nanomaterials for cancer immunotherapy

Cited by 232 publications

References 272 publications

Immunomodulatory Nanosystems

Immunomodulatory Nanosystems

Non‐viral gene delivery for cancer immunotherapy

Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination

Contact Info

Product

Resources

About